See more
Publication date: 26.05.2024
A new list of over-the-counter medicines prohibited from advertising has been approved
Introduction
The Ministry of Health of Ukraine has approved a new list of medicines prohibited for advertising, which are available without a prescription. The corresponding Order No. 457 was adopted on March 18, 2024 and will enter into force on the day of its official publication. This order will replace the previous order No. 1295 dated July 18, 2023, the effect of which was suspended until March 1, 2024 by the order of the Ministry of Health No. 1894.
The main changes
Reduction of the number of medicinal products prohibited for advertising
The new list approved by Order No. 457 contains 407 items, while the previous list approved by Order No. 1295 included 513 items. This indicates a significant reduction in the number of non-prescription drugs, the advertising of which is prohibited.
Reasons for changes
Although no official comments have been made on the reasons for such a reduction in the list, it can be assumed that the changes were made in order to optimize the regulation of drug advertising and take into account new medical research and recommendations. This may be related to a review of the effectiveness and safety of some drugs, as well as to a change in approaches to informing the population about medicinal products. You may be interested in the following articles: lawyer's consultation, lawyer's consultation, document analysis, legal situation analysis, written consultation, document review by a lawyer, lawyers' documents, lawyer's help online, lawyer online, legal opinion, lawyer's legal opinion, lawyer online.Impact on the pharmaceutical market
For manufacturers and distributors
Manufacturers and distributors of medicinal products should take into account the new list when planning marketing strategies. Reducing the number of prohibited drugs for advertising can open up new opportunities for advertising campaigns, but it is important to comply with current legislation and ethical standards.
For consumers
For consumers, these changes could mean greater access to information about over-the-counter medicines. At the same time, it is important to remember the need for a critical attitude to advertising materials and consultation with medical specialists before using any medicinal products.
Conclusion
The approval of the new List of medicinal products prohibited for advertising, which are available without a prescription, is an important step in the regulation of the pharmaceutical market of Ukraine. Reducing the number of prohibited drugs for advertising can contribute to greater transparency and awareness of consumers, but at the same time requires a responsible approach from manufacturers, distributors and consumers regarding the use and advertising of medicinal products.
From the perspective of the pharmaceutical market, changes in the List may affect the marketing and advertising strategies of manufacturers. Reducing the number of drugs prohibited from advertising can open up new opportunities for product promotion, but it also requires careful analysis of market trends and legislative requirements.
